BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...Ipsen added through its 2019 takeout of Clementia Pharmaceuticals Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Inc. hired Michael Harvey as SVP, drug development. Harvey was VP, drug development and Montreal site head at Clementia Pharmaceuticals Inc....
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...two candidates to treat rare disease FOP and the key to its billion-dollar acquisition of Clementia...
...to determine the appropriate patient population in which to continue palovarotene’s development in FOP (see “Clementia...
...MO-Ped trial for the latter (see “Hold Muddies Timeline” ). Ipsen’s February 2019 deal for Clementia Pharmaceuticals Inc....
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

...plc (LSE:AZN; NYSE:AZN) became the first anti-PD-L1 antibody approved in China. Ipsen takes impairment on Clementia...
...partial impairment on palovarotene, the rare bone disease candidate behind its $1 billion acquisition of Clementia Pharmaceuticals Inc....
...in a Phase III trial to treat fibrodysplasia ossificans progressiva (see “Ipsen’s $1B Bet on Clementia...
BioCentury | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

...the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia...
...trial is annualized change in new HO volume vs. the natural history of the disease. Clementia...
...in jeopardy any additional payout from Ipsen to Clementia shareholders. The February 2019 acquisition of Clementia...
BioCentury | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

...company obtain more innovative assets through deals, including this year’s acquisition of rare disease play Clementia Pharmaceuticals Inc....
BioCentury | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

...below €6.5 billion from more than €7.7 billion. Ipsen obtained palovarotene via its acquisition of Clementia Pharmaceuticals Inc....
...In its 3Q19 earnings call, Ipsen said it would delay the NDA submission, which Clementia...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...Inc. Repare Therapeutics Inc. hired Steve Forte as EVP and CFO. Forte was CFO of Clementia...
BioCentury | Oct 16, 2019
Company News

Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

...progressiva (FOP), an ultra-rare, progressive bone disease. Ipsen obtained that program via its acquisition of Clementia Pharmaceuticals Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...SIX:ROG; OTCQX:RHHBY) Spark Therapeutics Inc. (NASDAQ:ONCE) 2/25/19 $4,800.0 NA NA $4,800.0 Ipsen Group (Euronext:IPN; Pink:IPSEY) Clementia Pharmaceuticals Inc....
...Roche’s $4.8 billion acquisition of Spark Therapeutics Inc.; and Ipsen Group’s $1 billion acquisition of Clementia Pharmaceuticals Inc....
...Co. (NYSE:BMY), New York, N.Y. CanSino Biologics Inc.(HKSE:6185), Tianjin, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clementia Pharmaceuticals Inc....
Items per page:
1 - 10 of 46
BioCentury | Dec 12, 2020
Product Development

Ipsen is casting a wider BD net under new CEO Loew

...Ipsen added through its 2019 takeout of Clementia Pharmaceuticals Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...Inc. hired Michael Harvey as SVP, drug development. Harvey was VP, drug development and Montreal site head at Clementia Pharmaceuticals Inc....
BioCentury | May 29, 2020
Management Tracks

Leaving Sanofi, Loew to guide Ipsen’s path forward for troubled musculoskeletal program

...two candidates to treat rare disease FOP and the key to its billion-dollar acquisition of Clementia...
...to determine the appropriate patient population in which to continue palovarotene’s development in FOP (see “Clementia...
...MO-Ped trial for the latter (see “Hold Muddies Timeline” ). Ipsen’s February 2019 deal for Clementia Pharmaceuticals Inc....
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

...plc (LSE:AZN; NYSE:AZN) became the first anti-PD-L1 antibody approved in China. Ipsen takes impairment on Clementia...
...partial impairment on palovarotene, the rare bone disease candidate behind its $1 billion acquisition of Clementia Pharmaceuticals Inc....
...in a Phase III trial to treat fibrodysplasia ossificans progressiva (see “Ipsen’s $1B Bet on Clementia...
BioCentury | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

...the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia...
...trial is annualized change in new HO volume vs. the natural history of the disease. Clementia...
...in jeopardy any additional payout from Ipsen to Clementia shareholders. The February 2019 acquisition of Clementia...
BioCentury | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

...company obtain more innovative assets through deals, including this year’s acquisition of rare disease play Clementia Pharmaceuticals Inc....
BioCentury | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

...below €6.5 billion from more than €7.7 billion. Ipsen obtained palovarotene via its acquisition of Clementia Pharmaceuticals Inc....
...In its 3Q19 earnings call, Ipsen said it would delay the NDA submission, which Clementia...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...Inc. Repare Therapeutics Inc. hired Steve Forte as EVP and CFO. Forte was CFO of Clementia...
BioCentury | Oct 16, 2019
Company News

Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

...progressiva (FOP), an ultra-rare, progressive bone disease. Ipsen obtained that program via its acquisition of Clementia Pharmaceuticals Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...SIX:ROG; OTCQX:RHHBY) Spark Therapeutics Inc. (NASDAQ:ONCE) 2/25/19 $4,800.0 NA NA $4,800.0 Ipsen Group (Euronext:IPN; Pink:IPSEY) Clementia Pharmaceuticals Inc....
...Roche’s $4.8 billion acquisition of Spark Therapeutics Inc.; and Ipsen Group’s $1 billion acquisition of Clementia Pharmaceuticals Inc....
...Co. (NYSE:BMY), New York, N.Y. CanSino Biologics Inc.(HKSE:6185), Tianjin, China Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clementia Pharmaceuticals Inc....
Items per page:
1 - 10 of 46